CME 14
Oncoogy & Theranostics Committee
Wednesday, October 21, 10:00-11:30

Session Title
Molecular Drug Imaging of Solid Tumours Including Microenvironment

Chairpersons
Irene Virgolini (Innsbruck, Austria)
David Taïeb (Marseille, France)

Programme
10:00 - 10:30 Clément Bailly (Nantes, France): Tumor Immunotargeting Using Innovative Radionuclides
10:30 - 11:00 Uwe Haberkorn (Heidelberg, Germany): Protease Fibroblast Activation Protein (FAP)-Targeted Radiotracers for New Applications in Non-Invasive Tumour-Characterization, Staging or Radio-Ligand Therapy
11:00 - 11:30 Daniëlle Vugts (Amsterdam, Netherlands): Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology - What Can We Learn From Initial Clinical Trials?

Educational Objectives
2. Advantages and disadvantages of various procedures based on the use of targeted antibodies.
3. Interaction of the microenvironment and challenges with regard to therapeutic applications.

Summary
The aim of this CME is to discuss various approaches in the non-invasive assessment of inherent molecular properties of solid tumors using novel radiopharmaceuticals. In particular, novel imaging methods based on the use of targeted antibodies are discussed. In addition, special attention is paid to the interaction of the microenvironment. Promising therapeutic applications are also shown based on this individualized diagnosis.

Key Words
Molecular Imaging, Treatment Monitoring, New Treatment Approaches, Solid Tumours, Microenvironment.